Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced las
Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.